Cancer Drug may be Useful in the Treatment of Arthritis, Multiple Sclerosis

by Savitha C Muppala on  July 3, 2010 at 6:47 PM Drug News
RSS Email Print This Page Comment
A drug which is currently used to treat cancer may assist in the treatment of a range of inflammatory diseases like arthritis, multiple sclerosis, inflammatory bowel disease, and lupus, reveal scientists.
 Cancer Drug may be Useful in the Treatment of Arthritis, Multiple Sclerosis
Cancer Drug may be Useful in the Treatment of Arthritis, Multiple Sclerosis
Advertisement

Japanese scientists used mice to show that bortezomib, currently used to treat cancers that affect white blood cells, induces cell death only in harmful (active and proliferating) T cells, leaving the rest unharmed.

Advertisement
If the results prove true in humans, it offers hope that this drugs or others similar to it might be used to treat inflammatory diseases without the side effects of current drugs that affect all T cells equally.

"Unfortunately, there are a lot of people who are suffering from autoimmune and inflammatory disease," said Koichi Yanaba, a scientist from the Department of Dermatology at Nagasaki University Graduate School of Biomedical Sciences who was involved in the research.

"We believe that this new-type remedy for autoimmune and inflammatory disease could successfully treat them in the near future," Yanaba added.

To make this discovery, scientists used two groups of mice-the first treated with bortezomib and the second with saline. Researchers induced contact hypersensitivity reaction with oxazolone, a chemical allergen used for immunological experiments and found that bortezomib significantly inhibited the contact hypersensitivity responses.



Results strongly suggest that bortezomib treatment enhanced T cell death by inhibiting NF-kappa B activation, which plays a key role in regulating the immune response to infection.

This in turn led to the suppression of inflammatory responses in immune cells by reducing interferon-gamma production.

The study has been published in the July 2010 print issue of the Journal of Leukocyte Biology.

Source: ANI
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Drug Toxicity Cancer and Homeopathy Chemotherapy Signature Drug Toxicity Cancer Facts Cancer Tattoos A Body Art Infectious Mononucleosis Arthritis Oncology Drug Delivery Systems 
Advertisement

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive